Study of Comprehensive Treatment Effects on Inflammation-Associated Rapidly Progressive Coronary Artery Disease IR-CAD

What this Trial Is About

Researchers are studying a special type of coronary artery disease called inflammation-associated rapidly-progressive coronary artery disease IR-CAD, which differs from typical atherosclerotic coronary artery disease. This type progresses quickly, recurs often, and responds poorly to standard treatments after procedures like percutaneous coronary intervention PCI. The study aims to evaluate the effectiveness and safety of a comprehensive treatment approach in patients with IR-CAD by comparing their health outcomes before and after receiving the treatment. The comprehensive treatment includes intensified secondary prevention for atherosclerotic coronary artery disease, immunosuppressive therapy using glucocorticoids and other agents, coronary revascularization procedures such as PCI or coronary artery bypass graft CABG, supportive therapies to manage side effects, and lifestyle changes like a healthy diet, regular exercise, and quitting smoking. Patients receive this treatment and are followed for 24 months to assess its impact. Participants will be monitored through various assessments including major adverse cardiovascular events MACE, target vessel related MACE, exercise capacity tests like walking distance and squats, coronary lesion imaging, and inflammation markers such as erythrocyte sedimentation rate and C-reactive protein. Safety is also tracked by monitoring major bleeding and severe infection events. The study compares these outcomes before treatment initiation and up to 24 months after comprehensive treatment starts.

Efficacy and Safety of Comprehensive Treatment in Patients With IR-CAD: a Self-controlled Cohort Study